Rua Bioscience reported FY24 revenue growth, ongoing losses, and a capital-light international expansion strategy. Shareholders voted on auditor remuneration and a new share issue, with plans to raise NZ$3.1m and target new markets in FY25.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.